Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J.

Cancer Discov. 2018 Jun 8. pii: CD-17-1246. doi: 10.1158/2159-8290.CD-17-1246. [Epub ahead of print]

PMID:
29884728
2.

Reply to S.C. Formenti et al.

Luke JJ, Chmura SJ.

J Clin Oncol. 2018 Jun 5:JCO2018790980. doi: 10.1200/JCO.2018.79.0980. [Epub ahead of print] No abstract available.

PMID:
29870292
3.

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent.

Jutzy JMS, Lemons JM, Luke JJ, Chmura SJ.

Int J Breast Cancer. 2018 May 16;2018:4786819. doi: 10.1155/2018/4786819. eCollection 2018. Review.

4.

Further evidence to support judicious use of antibiotics in patients with cancer.

Luke JJ, Pal SK.

Ann Oncol. 2018 Apr 24. doi: 10.1093/annonc/mdy153. [Epub ahead of print] No abstract available.

PMID:
29688263
5.

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R.

J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x.

6.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

PMID:
29437535
7.

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer.

Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJ.

Oncotarget. 2017 Dec 15;9(4):4375-4384. doi: 10.18632/oncotarget.23315. eCollection 2018 Jan 12.

8.

Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.

Yanagita M, Luke JJ, Hodi FS, Jänne PA, Paweletz CP.

Melanoma Res. 2018 Apr;28(2):89-95. doi: 10.1097/CMR.0000000000000431.

PMID:
29406397
9.

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF.

Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290.

PMID:
29302014
10.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

11.

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT.

Cancer. 2018 Jan 15;124(2):315-324. doi: 10.1002/cncr.31044. Epub 2017 Oct 4.

PMID:
28976556
12.

Recent insights into the use of combination immunotherapy in solid tumors.

Luke JJ.

Clin Adv Hematol Oncol. 2017 Aug;15(8):588-591. No abstract available.

PMID:
28949945
13.

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M.

Clin Chem. 2017 Jul;63(7):1190-1195. doi: 10.1373/clinchem.2016.267849. Epub 2017 May 17. No abstract available.

PMID:
28515097
14.

Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI.

Cancer Immunol Res. 2017 May;5(5):357-362. doi: 10.1158/2326-6066.CIR-16-0287. Epub 2017 Apr 10.

15.

Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Luke JJ, Flaherty KT, Ribas A, Long GV.

Nat Rev Clin Oncol. 2017 Aug;14(8):463-482. doi: 10.1038/nrclinonc.2017.43. Epub 2017 Apr 4. Review.

16.

Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.

Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, Weinberg J, Donahue H, Bailey N, Hodi FS, Buchbinder EL, Ott PA.

Cancer Immunol Res. 2017 Apr;5(4):286-291. doi: 10.1158/2326-6066.CIR-16-0302.

17.

Mechanistic and pharmacologic insights on immune checkpoint inhibitors.

Sweis RF, Luke JJ.

Pharmacol Res. 2017 Jun;120:1-9. doi: 10.1016/j.phrs.2017.03.012. Epub 2017 Mar 18. Review.

18.

PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology.

Shah S, Wood K, Brisson R, Karrison T, Hensing T, Luke JJ, Patel JD.

J Thorac Oncol. 2016 Nov;11(11S):S310. doi: 10.1016/j.jtho.2016.09.098. Epub 2016 Oct 28. No abstract available.

19.

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. Epub 2016 Nov 11.

20.

Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.

Shah S, Ward JE, Bao R, Hall CR, Brockstein BE, Luke JJ.

Cancer Immunol Res. 2016 Nov;4(11):903-909. Epub 2016 Sep 16.

21.

The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA.

Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.

22.

Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.

Wood K, Luke JJ.

Curr Oncol Rep. 2016 Nov;18(11):67. doi: 10.1007/s11912-016-0554-5. Review.

PMID:
27613168
23.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ.

J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.

24.
25.

ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.

Luke JJ, LoRusso P, Shapiro GI, Krivoshik A, Schuster R, Yamazaki T, Arai Y, Fakhoury A, Dmuchowski C, Infante JR.

Cancer Chemother Pharmacol. 2016 Mar;77(3):549-58. doi: 10.1007/s00280-016-2967-0. Epub 2016 Jan 25.

26.

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.

Munhoz RR, D'Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, Qin LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA.

Oncologist. 2015 Nov;20(11):1245-6. doi: 10.1634/theoncologist.2015-0245. Epub 2015 Oct 8.

27.

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.

Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, Chin G, Luke JJ, Ott PA, Hodi FS, Mihm MC Jr, Lin JY, Werchniak AE, Haynes HA, Bailey N, Liu R, Murphy GF, Lian CG.

Clin Epigenetics. 2015 Jun 9;7:59. doi: 10.1186/s13148-015-0091-3. eCollection 2015.

28.

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.

Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS.

Cancer Immunol Res. 2015 Sep;3(9):986-91. doi: 10.1158/2326-6066.CIR-15-0066. Epub 2015 May 5.

29.

Have we won the race in the treatment of advanced melanoma-or are we just learning to walk?

Luke JJ.

Oncology (Williston Park). 2015 Feb;29(2):136, 138-9. No abstract available.

30.
31.

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.

D' Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, Luke JJ, Hartley EW, Antonescu CR, Tap WD, Schwartz GK.

Cancer Chemother Pharmacol. 2015 Mar;75(3):629-38. doi: 10.1007/s00280-015-2689-8. Epub 2015 Feb 12.

32.

Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.

Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB.

Clin Cancer Res. 2015 Feb 15;21(4):749-55. doi: 10.1158/1078-0432.CCR-14-2353. Epub 2014 Dec 23.

33.

The biology and clinical development of MEK inhibitors for cancer.

Luke JJ, Ott PA, Shapiro GI.

Drugs. 2014 Dec;74(18):2111-28. doi: 10.1007/s40265-014-0315-4. Review.

PMID:
25414119
34.

Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.

Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA.

JAMA Dermatol. 2015 Feb;151(2):195-9. doi: 10.1001/jamadermatol.2014.2233.

PMID:
25321335
35.

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.

Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, Lawson D, Bartell H, Kudchadkar R, Gunter NT, Mehnert JM, Lipson EJ.

J Immunother Cancer. 2014 Oct 14;2(1):33. doi: 10.1186/s40425-014-0033-1. eCollection 2014.

36.

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD.

Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. doi: 10.1111/pcmr.12304. Epub 2014 Sep 1. Review.

37.

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, Johnson BE; Cell Free DNA Working Group.

J Natl Cancer Inst. 2014 Aug 8;106(8). pii: dju214. doi: 10.1093/jnci/dju214. Print 2014 Aug.

PMID:
25106647
38.

New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.

Luke JJ, Ott PA.

Drug Healthc Patient Saf. 2014 Jun 24;6:77-88. doi: 10.2147/DHPS.S39568. eCollection 2014. Review.

39.

Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.

Luke JJ, Lezcano C, Hodi FS, Murphy GF.

J Clin Oncol. 2015 Feb 20;33(6):e32-5. doi: 10.1200/JCO.2013.49.7735. Epub 2014 Mar 10. No abstract available.

40.

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA.

Clin Cancer Res. 2014 Mar 15;20(6):1698-1705. doi: 10.1158/1078-0432.CCR-13-2482. Epub 2014 Jan 15.

41.

Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?

Luke JJ, Ott PA.

Expert Opin Pharmacother. 2013 Dec;14(18):2457-62. doi: 10.1517/14656566.2013.849244. Epub 2013 Oct 21.

PMID:
24138302
42.

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.

Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2.

43.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

44.

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.

Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28.

45.

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist. 2013 Jun;18(6):717-25. doi: 10.1634/theoncologist.2012-0391. Epub 2013 May 24. Review.

46.

Chemotherapy in the management of advanced cutaneous malignant melanoma.

Luke JJ, Schwartz GK.

Clin Dermatol. 2013 May-Jun;31(3):290-7. doi: 10.1016/j.clindermatol.2012.08.016. Review.

47.

Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.

Luke JJ, Rubinstein LV, Smith GL, Ivy SP, Harris PJ.

Melanoma Res. 2013 Apr;23(2):152-8. doi: 10.1097/CMR.0b013e32835f73b2.

PMID:
23411478
48.

Advances in the systemic treatment of cutaneous sarcomas.

Luke JJ, Keohan ML.

Semin Oncol. 2012 Apr;39(2):173-83. doi: 10.1053/j.seminoncol.2012.01.004. Review.

49.

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.

Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK.

Clin Cancer Res. 2012 May 1;18(9):2638-47. doi: 10.1158/1078-0432.CCR-11-3203. Epub 2012 Feb 28.

50.

Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.

Luke JJ, Hodi FS.

Clin Cancer Res. 2012 Jan 1;18(1):9-14. doi: 10.1158/1078-0432.CCR-11-2197. Epub 2011 Nov 14.

Supplemental Content

Support Center